Vickor Medical Wins First Prize at Wuhan's 7th 'Gongyou Cup' Staff Innovation and Entrepreneurship Competition with Its DOCS VALVE® Transcatheter Aortic Valve Replacement System
Vickor
Structural Heart Disease Minimally Invasive Intervention Product Developer
On September 30, hosted by Wuhan Federation of Trade Unions, Wuhan Women's Federation, Wuhan Association for Science and Technology, Wuhan Science and Technology Innovation Bureau, and Wuhan Human Resources and Social Security BureauFinal of the 7th "Gongyou Cup" Wuhan Employee Entrepreneurship and Innovation CompetitionSuccessfully concluded. The competition, themed "Building a Fulcrum, Engineering Jiangcheng," featured four specialized tracks: scientific innovation, advanced manufacturing, modern services, and modern agriculture, collecting a total of 215 entries. After fierce competition,Vickor's "Transcatheter Aortic Valve Replacement System" Wins First Prize!
As an innovative force deeply engaged in the high-end medical device field, Vickor's entry of "Transcatheter Aortic Valve Replacement System" in this competition is highly consistent with the requirements of the contest."High technological content, easy to transform, and broad market prospects"The requirements highlight the project's hardcore advantages. This product directly addresses the clinical pain points in cardiovascular disease treatment, excelling not only in safety and efficacy but also playing a strategically important role in advancing the domestic production of high-end medical devices and promoting the transformation and upgrading of the healthcare industry. It perfectly aligns with the core mission of the competition: "driving industrial development and serving public health needs."
At the competition site,General Manager Wang XueliVividly interpreting the technical highlights of the transcatheter aortic valve replacement system, covering its development process, clinical application outcomes, and market development planning. She pointed out that with continuous technological iteration, aortic valve replacement devices have evolved from traditional mechanical valves to advanced transcatheter aortic valve replacement systems (TAVR), achieving a disruptive leap from open surgery to minimally invasive treatment. Additionally, she emphasized the strong growth momentum of market demand, stressing the need for technological innovation and market segmentation strategies.Comprehensively enhance the performance, safety, and market competitiveness of the product.
From core technology breakthroughs to product landing and transformation, from solving clinical pain points to building a future industrial ecosystem, the Vickor medical team won high recognition from the judges with their professional and detailed presentation and the broad prospects contained in the project.Finally, they stood out in the fierce competition and won the highest honor of the competition.
This prestigious award not only represents high recognition of Vickor's technological innovation capabilities but also serves as a vivid interpretation of the company’s commitment to the philosophy of "employee entrepreneurship and innovation, serving urban development." Looking ahead, Vickor will continue to focus on technology-driven initiatives, deepen its expertise in the high-end medical device field, and accelerate the transformation of scientific and technological achievements.To build Wuhan into a science and technology innovation center with influence across China, and to continuously inject "Vickor momentum" into the in-depth implementation of the Healthy China strategy!
DOCS VALVE®Transcatheter Aortic Valve Replacement System
DOCS VALVE®The Transcatheter Aortic Valve Replacement System is an artificial valve with independent intellectual property rights. It was primarily designed by a team of structural heart disease specialists and developed through close collaboration between medical professionals and engineers. Its core clinical value lies in breaking through the application contraindications for large annuli and pure regurgitation, meeting the dual indication requirements for both stenosis and regurgitation. Additionally, DOCS VALVE®Adopted an innovative aortic root coaxial adjustment strategy, making the surgical process safer and more simplified, without the need for rapid pacing, general anesthesia sedation, or the risk of circulatory collapse, effectively enhancing surgical safety.
For Medical Professionals Only
Not intended for medical services and product promotion or recommendation